bioAffinity Technologies (NASDAQ:BIAF) Stock Rating Upgraded by Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Monday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, bioAffinity Technologies has a consensus rating of “Sell”.

bioAffinity Technologies Stock Down 0.8%

BIAF stock opened at $0.49 on Monday. The stock has a market capitalization of $2.30 million, a PE ratio of -0.07 and a beta of -1.05. The company has a fifty day moving average of $0.88 and a 200-day moving average of $1.63. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.34 and a current ratio of 1.36. bioAffinity Technologies has a one year low of $0.46 and a one year high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.10) by $1.46. The firm had revenue of $1.51 million during the quarter, compared to analysts’ expectations of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 196.80%.

Institutional Investors Weigh In On bioAffinity Technologies

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new position in shares of bioAffinity Technologies in the 4th quarter valued at about $36,000. Scientech Research LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter valued at about $49,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies during the first quarter worth about $164,000. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.